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ABSTRACT
We analyzed the frequency and relevance of mutations in the coding
region of the androgen receptor (AR) in genomic DNA extracted from 137
specimens of prostate cancer. The specimens were obtained from the
primary tumors of patients affected by stage B disease [15 nonmicrodis-
sected (group 1A) and 84 microdissected (group 1B)] and from the met-
astatic deposits of individuals with stage D1 disease [8 nonmicrodissected
(group 2A) and 30 microdissected (group 2B)] who had not undergone
androgen ablation therapy. The study was conducted by PCR-single
strand conformational polymorphism (SSCP) analysis of exons 2–8 in the
four groups and direct sequence analysis of exon 1 in group 1B. As positive
and negative controls, we used genomic DNA extracted from genital skin
fibroblasts of patients affected by various forms of androgen resistance
with known mutations in the AR. To control for genetic instability,
PCR-SSCP analysis of exon 2 of the human progesterone receptor was
carried out on each specimen.
The overall number of mutations detected was 11 (8%). No mutations
were detected in any of the 99 patients with stage B disease. Eleven
mutations were detected in exons 2–8 in 8 of the 38 patients with stage D1
disease (all in group 2B). Simultaneous analysis of exon 2 of the proges-
terone receptor was carried out, and no SSCP changes were identified.
These data suggest that AR mutations are rare and presumably do not
play a role in the initial phase of prostatic carcinogenesis. The presence of
a significant number of AR mutations in metastatic disease indicates that
mutations of this molecule may play a role in the most advanced phases of
the natural history of this disease, either by facilitating growth or acqui-
sition of the metastatic phenotype.
INTRODUCTION
Prostate cancer is the most frequently diagnosed malignancy in men
and the second leading cause of cancer death in men in the United
States (1). The development, growth, and differentiation of the normal
prostate is regulated by androgens, which exert their effects by inter-
acting with the AR,3 a member of a superfamily of ligand-activated
nuclear transcription factors (2). Abnormal androgen biosynthesis or
inactivating mutations of AR are associated with absent or rudimen-
tary development of the prostate in 46,XY individuals (3). There is
anecdotal evidence that prostate cancer does not develop in men
castrated before puberty, and that androgen is required for the exper-
imental induction of prostate cancer in animals. Therefore, a normal
AR signaling pathway is a necessary requirement, not only for the
development of a normal prostate but presumably also for the devel-
opment of prostate cancer.
Radical prostatectomy is the main curative treatment for men with
organ-confined disease. Most men with non-organ-confined disease
will undergo palliation with radiation or androgen ablation. Androgen
ablation successfully shrinks primary and metastatic lesions by induc-
ing apoptosis of androgen-dependent prostate cancer cells (4) in up to
80% of the cases (5). Unfortunately, prostate cancer is a heterogene-
ous lesion and at the time of diagnosis may contain foci of both
androgen-dependent and -independent cells (6). Androgen-indepen-
dent cells escape apoptosis induced by androgen ablation (7) and by
many cytotoxic drugs. They continue to proliferate and metastasize,
despite profound changes in the surrounding hormonal milieu, and
represent the most direct threat to patient survival. There is evidence
that the AR is expressed in all stages of prostate cancer evolution,
including prostatic intraepithelial neoplasia (8), primary (9, 10) and
metastatic (11, 12) disease, both before and after androgen ablation
therapy. Few prostate cancers are AR negative (13), and thus, even the
androgen-independent tumors express the AR protein.
In the wake of the earlier identification of “outlaw estrogen recep-
tors” in breast cancer (14), the possibility that point mutations in the
AR may account for progression from androgen-dependent to andro-
gen-independent growth has been a popular theory. Numerous inves-
tigators have used PCR-SSCP of DNA extracted from foci of prostate
cancer to search for AR variants, both in clinically detectable disease
and in latent prostate cancer.
A review of published data (Refs. 15–36; reviewed in Ref. 37)
shows that there is still considerable controversy in the field. A total
of 581 cases of clinically detectable prostate cancer have been ana-
lyzed at the molecular level for the presence of AR mutations. To
date, a total of 47 mutations (frequency, 8%) causing an amino acid
change or addition have been detected. Interestingly, 22 of these
mutations (46% of total) were reported by three groups from a total of
59 patients (frequency of mutations in these 59 patients, 37%; Refs.
21, 26, and 34). The remaining 25 mutations were detected in 522
patients (frequency, 4.7%). Methodological variables and patient sam-
pling may be responsible for these discrepancies in the literature. For
instance, Tilley et al. (34) demonstrated that variables correlating with
increased prevalence of AR mutations are the use of tumor-enriched
DNA after microdissection of the sample and analysis of exon 1.
Another potential methodological variable is the quality of DNA
extracted from paraffin-embedded tissue, which according to some
reports is not optimal and may account for an increased frequency of
PCR infidelity (38).
In view of the controversies still existing in the field, we have
studied the molecular structure of the AR in a large series of speci-
mens derived from stage B prostate cancers and from metastatic
deposits to pelvic lymph nodes (stage D1). We have determined the
importance of using microdissected versus nonmicrodissected speci-
mens, of extracting DNA from fresh versus archival tissue, and of
analyzing exon 1 to the overall incidence of detection of receptor
mutations. We report a significant increase in AR mutations in met-
astatic (stage D1) compared with localized (stage B) prostate cancers.
MATERIALS AND METHODS
Tissue. Specimens used in these studies were obtained from the tissue bank
of one of the authors (M. I.) and from the tissue bank of the Baylor Specialized
Programs of Research Excellence for prostate cancer. The protocol was ap-
proved by the Institutional Review Board of Baylor College of Medicine. We
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analyzed DNA from 99 tumors of patients with stage B disease who underwent
total prostatectomy between 1986 and 1998. In 15 of these patients, genomic
DNA was extracted from frozen nonmicrodissected cancer specimens of ;10
mg (group 1A), which were isolated according to the procedure of Wheeler and
Lebovitz (39) and contain at least 25% of cancer. The remaining 85 samples
(group 1B) were snap frozen and extracted after ascertaining the presence of at
least 50% neoplastic tissue by frozen section analysis, as described by Ittmann
et al. (40). High molecular weight genomic DNA was extracted from the
powdered samples of group 1A using 10 volumes of extraction buffer [10 mM
Tris-Cl (pH 8.0), 0.1 M EDTA (pH 8.0), 10 mg/ml RNase, and 0.5% SDS] for
1 h at 37°C. Proteinase K at a final concentration of 100 mg/ml was then added
and incubated at 50°C for 3 h. After three phenol extractions, the aqueous
phase was dialyzed in 50 mM Tris (pH 8.0) at 4°C for 24 h. One mg of this
highly purified material was used in each PCR reaction.
We also studied 38 paraffin-embedded pelvic lymph nodes resected from
patients with stage D prostate cancer (group 2). Of these, 8 were not micro-
dissected and contained 20–25% cancer (group 2A). Thirty were microdis-
sected and contained 90–95% cancer (group 2B). To enrich for tumor-derived
DNA, specimens of group 2B were cut in three sections of 4, 25, and 4 mm.
After H&E staining, a pathologist identified the region containing 100% cancer
in the two 4-mm sections. The 25-mm region located between the two adjacent
sections containing 100% cancer was microdissected and then deparaffinized
in xylene and ethanol and precipitated by microcentrifugation at 4°C. Genomic
DNA was extracted through digestion in a 100-ml volume [10 mM Tris (pH
8.3), 50 mM KCl, 2.5 mM MgCl2, 0.45% Tween 20, and 0.1 mg of proteinase
K] at 65°C for 2 h, followed by denaturation of proteinase K at 95°C for 10
min. Depending on the final yield, 4–10 ml of genomic DNA were used in each
PCR reaction.
PCR-SSCP. PCR amplification of exons 2–8 was performed using a MJ
Research Thermal Cycler and the primers reported previously (41), with the
exception of exon 4, which was amplified using two sets of overlapping
primers to generate products within the acceptable range that maintains SSCP
sensitivity. The primers used for exon 4 were the following: IV-S, TGATA-
AATTCAAGTCTCTCTTCCTT; IV-AS, ACACACTACACCTGGCTCAAT-
GGCTT; IVB-S, CAGTGTCACACATTGAAGGCTATGAA; and IVB-AS,
CACTAAATATGATCCCCCTTATCTC.
Eight sets of overlapping sense (S) and antisense (AS) primers were used to
amplify exon 1. The coordinates of these oligonucleotides are derived from the
sequence of Tilley et al. (2). Primer E1-VIIIAS is derived from the region of
intron 1 adjacent to the 39 of exon 1 (41). The eight sets of primers are: E1-IS,
139TGGAAGATTCAGCCAAGCTCAAG161; E1-IAS, 417CTGCTGCTGC-
CTGGGGCTAGTCTC394; E1-IIS, 280AGGCACCCAGAGGCCGCGAGCG-
CAG304; E1-IIAS, 579GCTGGCGGCCACGGCGGCTCCAGG556; E1-IIIS,
514TCGGCCCTGGAGTGCCACCCCGAGA538; E1-IIIAS, 912CGCCTCCA-
CACCCAGGCCCATGGA889; E1-IVS, 612GGACGAGGATGACTCAGCT-
GCCCCA636; E1-IVAS, 1113TAGCCCTTTGGTGTAACCTCCCTTG1089;
E1-VS, 803CTCCCACTTCCTCCAAGGACAA824; E1-VAS, 1264AGCC-
AGTGGAAAGTTGTAGTAGTC1240; E1-VIS, 1207GCACTGGACGAG-
GCAGCTGCGTAC1230; E1-VIAS, 1506CCACACGGTCCATACAACTG-
GCC1483; E1-VIIS, 1401CGCGGGTGCAGCGGGACCCGGTTCT1425;
E1-VIIAAS, 1660ACACATCAGGTGCGGTGAAGTCGCT1636; E1-VIIIS,
1578GGGAGCTGTAGCCCCCTACGGCTAC1602; and E1-VIIIAS, CGAAA-
GCGACATTTCTGGAAGGAAA. Exon 2 of the human PR was also ampli-
fied and used as a control using oligonucleotides: PR-S, GCATTTCAAGGC-
CGGATTCAGAAGC; and PR-AS, AGGAGCCTACCTTCCATTGCCC (42).
Because the process of confirming the identification of point mutations used
very stringent criteria and numerous PCR reactions (see below), there was
insufficient genomic DNA available to analyze exon 1 of the AR gene in
groups 1A, 2A, and 2B; however, we were able to analyze all eight exons in
group 1B.
The PCR reaction involved denaturation at 100°C for 30 s, annealing and
extension at 68°C for 90 s for 35 cycles using 2.5 units of Taqara (Pan Vera
Corporation, Madison WI), and 1 ml of [32P]dCTP per reaction. The size and
integrity of the PCR product and the absence of contamination in the negative
control sample (in which no DNA was added) were confirmed on 2% agarose
gels. SSCP analysis was performed according to the published procedures
(43–45). Briefly, 5 ml of PCR sample plus 20 ml of formamide loading dye
(0.05% bromphenol blue, 0.05% xylene cyanol, 50 mM EDTA, and 20 mM
NaOH in deionized formamide) were boiled for 10 min, snap-frozen in dry ice,
and thawed. Six ml of the samples were electrophoresed on a 6% nondenatur-
ing polyacrylamide gel at 400 V for 14–24 h, depending on the fragment
generated. A nondenatured wild-type AR control was run in parallel with the
other denatured samples to determine the mobility of the double-stranded
DNA. As an internal control, each gel was run with a positive and a negative
control (i.e., a PCR product generated from the genomic DNA of patients with
testicular feminization that were known to have a wild-type or mutated
sequence in exons 2–8). This genomic DNA was used to optimize the SSCP
conditions. For instance, in most cases a run of 12–14 h was sufficient to detect
the abnormal SSCP migration of the positive control; however, in the case of
exons 3 and 7, a run of 22–24 h was necessary. This genomic DNA was the
generous gift of Dr. M. J. McPhaul (University of Texas Southwestern Medical
Center, Dallas, TX). Each of the positive mutant AR controls used in these
studies has been characterized and published (41, 46–53). After electrophore-
sis, gels were dried and exposed to X-ray films for autoradiography at 280°C.
DNA Sequencing. Stringent criteria were adopted to eliminate PCR arti-
facts. The presence of a variant SSCP shift was confirmed in three independent
PCR reactions. These PCR products were divided into three aliquots, of which
one was run in the SSCP gel and one in an agarose gel to verify the presence
of the correct amplified product and the absence of background in the negative
control. The third aliquot was TA-subcloned into the pCR2.1-TOPO plasmid
(Invitrogen, Carlsbad, CA) and dideoxy-sequenced (54) in a denaturing poly-
acrylamide gel, using the Sequenase 2.0 sequencing kit (United States Bio-
chemical Corp., Cleveland, OH). Each mutation was confirmed a minimum of
three times from multiple clones (up to 20) obtained from at least three
independent PCR amplifications. Sequencing was performed in both the sense
and antisense orientations.
Exon 1 of group 1B was analyzed by direct sequencing of the PCR product
using an automated sequencer (Perkin-Elmer Sequencer 310). Sequence anal-
ysis was performed multiple times (up to 10) from the product of at least two
PCR amplifications. Each reaction mix consisted of 30–90 ng of the purified
PCR product, 3.2 pmol of primer, and 4 ml of Big Dye Terminator dye mix
(Perkin-Elmer Applied Biosystems, Foster City CA). PCR sequencing was
performed at 96°C for 30 s, 50°C for 15 s, and 60°C for 4 min for a total of
25 cycles. The resulting DNA was then precipitated in ethanol, dissolved in 12
ml of formamide, and analyzed on the automatic sequencer. Computer analysis,
and careful reading of the sequencer print out were used to distinguish
mutations. All nucleotides of exon 1 were sequenced except the polyQ and
polyG repeats. AR amino acid numbering reported in this study is based on an
assumed length of 919 amino acids to be consistent with the AR mutation web
site.4 To determine the sensitivity of our automated sequencing technique, we
performed serial dilutions of mutant and wild-type genomic DNA [ranging
from 1:1 to 1:1/10 (wild type:mutant)]. Each dilution was amplified and
sequenced, and in each instance a mutation of the correct nucleotide was
detected (not shown). These data indicate that direct sequencing identifies
point mutations if they are present in 10% of the genomic DNA. Because
previous pilot experiments in our laboratory have demonstrated that a mutation
can correctly be identified by SSCP if it is present in 10–15% of the genomic
DNA, we conclude that direct sequencing is at least as sensitive as SSCP in
detecting point mutations.
RESULTS
Nonmicrodissected Stage B Prostate Cancers (Group 1A).
SSCP analysis of 15 nonmicrodissected specimens isolated from
patients with stage B disease showed the absence of AR variants in
each of the seven exons (2–8) analyzed. Representative pictures
showing SSCP analysis of exons 3 and 7 are shown in Fig. 1. In view
of the absence of reproducible SSCP shifts, sequencing analysis was
not performed with these samples, and it was assumed that no muta-
tion was present. Reproducible SSCP shifts were obtained in genomic
DNA extracted from patients with androgen resistance and proven
mutations of AR (Fig. 1), thus demonstrating that the SSCP conditions
were optimized to detect mutations. No SSCP shifts were detected in
4 Internet address: http://www.mcgill.ca/androgendb/data.htm.
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samples containing exon 2 of the human PR that were run in parallel
(not shown).
Microdissected Stage B Prostate Cancer (Group 1B). Group 1B
was microdissected to contain a minimum of 50% neoplastic tissue by
frozen section analysis. Analysis of exons 2–8 in the 84 patients
belonging to this group showed 14 SSCP variants. Sequence analysis
(in each case, a minimum of 10 templates) did not show any mutation
in 13 of these variants. In one case, we detected a 1-bp change
corresponding to codon 580 (AAG-AAA) that did not change the
amino acid residue. This was a germ-line polymorphism that was also
detected in the surrounding normal tissue and confirmed the ability of
our technique to detect single bp changes in the AR sequence. Direct
sequencing of exon 1 did not identify any mutation of the coding
sequence. No sequence abnormalities were detected in exon 2 of the
PR that was run in parallel. The positive controls from exons 2–8
yielded SSCP shifts in the exon, where they had been identified
previously, demonstrating that we were using optimized conditions
for AR mutation analysis.
Metastatic Lesions (Groups 2A and 2B). SSCP analysis of spec-
imens from groups 2A and 2B showed 19 reproducible shifts (in at
least two separate PCR reactions) in the seven exons that were
analyzed (four shifts in group 2A and 15 in group 2B). Sequence
analysis revealed 11 mutations (all in group 2B), 10 missense and 1
nonsense mutations (Table 1). Each mutation was detected at least
once in each of the three PCR amplifications performed for each exon
during the SSCP screening (Table 1). Fig. 2 shows the SSCP pattern
of the mutations detected in patients 3 and 20. Each of these mutations
was a somatic event, because wild-type sequences were also detected.
Four of these mutations were detected in patient 1 and involved exons
5 (A-748-T), 7 (S-865-P and Q-867-stop), and 8 (Q-919-R). Because
each exon was amplified individually from a pool of DNA derived
from many cells, it is impossible to know if these mutations were
present in the same AR molecule or even the same cell. We consis-
tently found two mutations in exon 7 of this patient. Because they
were never detected in the same template, they most likely represent
separate events that affected two individual AR molecules. The re-
maining seven mutations were detected in seven different patients and
affected exons 2 (in four cases), 3, 5, and 7.
The remaining six SSCP shifts of group 2B and the four SSCP
shifts of group 2A did not yield a reproducible base change when
subcloned and sequenced. Despite extensive sequence analysis of
these samples (in each case, at least 20 templates from three different
PCR amplifications), we were unable to identify a base change that
recurred more than once. In each instance, the majority were wild-
type sequences, and a minority (in 25–35% of the templates) were
unreproducible base changes (i.e., base changes that were never found
more than once in the 20 different templates that were sequenced).
Because we were unable to identify these base changes more than
once, they have not been taken into account. Because the phenomenon
of SSCP shifts followed by identification of unreproducible base
change was observed only in DNA obtained from paraffin-embedded
tissue, it is possible that fixation may affect the quality of this DNA.
This in turn may affect the fidelity of the PCR reaction, as described
previously by Shiao et al. (38). Exon 2 of the PR did not show any
SSCP abnormality.
Fig. 1. SSCP analysis of exons 3 and 7 of the androgen
receptor in 14 nonmicrodissected stage B prostate cancers
(group 1A). Samples were run in a nondenaturing poly-
acrylamide gel, as explained in “Materials and Methods.”
Known mutants for exons 3 (48) and 7 (53) were loaded
as a positive control in each reaction.
Table 1 Summary of the mutations identified in group 2B
Tumor Exon Mutation
Amino acid
change
No. of PCR-
SSCP
amplifications
No. of
mutated
templatesa
No. of
templates
sequenced
1 5 GCC-ACC A-748-T 3 8 12
1 7 TCC-CCC S-865-P 3 8 11
1 7 CAG-TAG Q-867-stop 3 4 16
1 8 CAG-CGG Q-919-R 3 3 20
3 2 GCC-GTC A-586-V 3 3 20
5 2 AAG-AGG K-580-R 3 3 20
8 7 AGA-GGA R-846-G 3 8 13
11 2 ACA-GCA T-575-A 3 5 15
12 2 GCT-TCT A-587-S 3 3 20
18 3 TGT-TAT C-619-Y 3 6 18
20 5 GTC-GCC V-757-A 3 5 17
a In every case, wild-type sequences were also identified in other templates, indicating
that each mutation was a somatic event. Each of these mutations was identified in at least
three separate PCR amplifications.
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DISCUSSION
Summary of the Data
Groups 1A and 1B. Two types of samples from patients affected
by stage B disease were studied. The analysis of group 1A (nonmi-
crodissected) was significant for the complete absence of AR muta-
tions. Because positive controls with known mutant DNA from pa-
tients with androgen resistance syndromes were analyzed in each
reaction and SSCP variants were identified in each of these speci-
mens, we conclude that the absence of AR mutations in these samples
was unlikely attributable to imperfect SSCP conditions. However,
because we were concerned that this negative result was because of a
failure to microdissect the tissue or to analyze exon 1, we obtained 84
prostate cancers specimens (group 1B) that had been microdissected
to contain a minimum of 50% neoplastic tissue. Previous analysis of
this material demonstrated loss of heterozygosity on 13q in ;30% of
the samples (55). This result is in agreement with several studies by
other groups and indicates that this DNA was indeed enriched with
tumor DNA. Because a large amount of genomic DNA was available
for group 1B, we were able expand our analysis to exon 1. Sequence
analysis demonstrated conclusively that no amino acid changes were
present in this group of patients, although a somatic polymorphism
was detected.
On the basis of the studies performed with groups 1A and 1B,
which represent almost 50% of all published stage B cases that have
been analyzed for AR mutations, we conclude that AR mutations are
quite rare in patients with clinically localized disease and usually do
not play a role in the initial phases of prostatic carcinogenesis. These
conclusions are largely based on the use of SSCP or direct sequencing
as screening techniques to detect mutations, and both these procedures
are sensitive if a mutation is present in at least 10–15% of the
genomic DNA. Thus, it could be argued that techniques more sensi-
tive could alter the apparent frequency of mutations detected. In
agreement with our findings, previous studies of other authors have
detected AR mutations only in 2.1% of patients with stage B disease
(15–18, 22–24, 29, 32, 33, 35). Thus, we believe that AR mutations
are exceptionally rare in this early phase of the natural history of
prostate cancer.
Metastatic Disease. In view of the controversies existing in the
field, we investigated patients with metastatic prostate cancer. We
microdissected metastatic tissue obtained from patients who were
unexpectedly found to have non-organ-confined disease on the frozen
sections of the regional lymph nodes analyzed at the time of radical
prostatectomy. Analysis of these cancers, all obtained before imple-
mentation of androgen ablation, demonstrated that AR mutations
occur in metastatic prostate cancer in contrast to stage B disease. A
total of 11 mutations was detected in this group of 38 patients.
Because four of these 11 mutations were in the same patient, AR
variants were present in 8 patients of 38 screened (i.e., 21%). We were
unable to analyze exon 1 in this group of patients, and a previous
report (34) has identified a significant number of AR mutations in
exon 1. Thus, the exact prevalence of AR mutations in stage D1
prostate cancer may be even higher than that established by our study.
Because no SSCP abnormalities were found in exon 2 of the PR, we
conclude that the relatively high prevalence of mutations in stage D1
disease is not attributable to generalized genetic instability, and that
specific mechanisms selecting these mutations may be involved. Be-
cause the patients described in this report were analyzed prior to
initiation of hormonal therapy, our findings also support the hypoth-
esis that cells with mutant AR can preexist androgen-ablative treat-
ments. The presence of AR mutations in metastatic deposits obtained
from patients with stage D1 disease confirms previous reports by
Taplin et al. (26, 27) in stage D2 and suggests that AR mutations may
play an active role in promoting the metastatic phenotype.
Characteristics of the Various Mutations Detected
A detailed analysis of the functional phenotype created by each
mutation is beyond the scope of this report and will be reported in
separate manuscripts. The mutations found in metastatic specimens,
S-865-P, Q867-stop, Q-919-R, A-586-V, K-580-R, R-846-G,
T-575-A, A-587-S, C-619-Y, and V-757-A, have never been de-
scribed before. Additionally, these amino acid residues have never
been affected by a mutation, according to the AR database web site.4
Although mutation A-748-T has never been described before, two
reports have identified mutations of codon 748. In one case (49),
mutation A-748-D was detected in a patient with a Reifenstein phe-
notype, and the functional analysis showed an increased dissociation
rate of [3H]mibolerone from receptors containing that mutation. In the
second case, A-748-V was detected in the prostate of a Japanese
patient affected by latent prostate cancer (25). No functional analysis
of this mutation was done. However, because residue 748 is in a
highly conserved region of the hormone-binding domain, mutations of
this codon were predicted to inactivate the AR protein.
Mutation Q-867-stop has never been described before. However,
previous investigators have studied the transcriptional activity of AR
molecules containing premature stop codons in regions surrounding
Q-867. Because these mutants [W-796-stop (46) and S-853-stop (53)]
Fig. 2. SSCP analysis of exons 5 (A), 2 (B), 3 (C), and 8 (D) in patients with stage D prostate cancer. A, Lane 9 p, SSCP pattern detected in exon 5 of patient 20. The sample run
in Lane 1 was an exon 5 mutant (W739R) described previously in a patient with androgen resistance (49). The sample run in Lane 2 was a control with known wild-type exon 5. The
samples run in Lanes 3–8 were from six patients with prostate cancer and had an SSCP migration pattern undistinguishable from the wild-type. B, Lane 11 p, abnormal SSCP pattern
detected in exon 2 of patient 3, compared with the migration pattern of a wild-type exon 2 in Lane 10. C, Lane 13 p, abnormal SSCP pattern detected in patient 18, compared with
the migration pattern of a wild-type exon 3 in Lane 12. D, Lane 15 p, abnormal SSCP pattern detected in patient 1 (exon 8), compared with the migration pattern of a wild-type exon
8 in Lane 14.
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were both transcriptionally silent, we predict by analogy that also
Q-867 is an AR mutation causing loss of transcriptional activity.
Role Played by the Different Methodological Variables
Differences in the methodologies of the various investigators may
account for the discrepant results in the different series. Failure to use
tumor-enriched DNA may account for the negative results that some
authors have published in the past. In view of this, we expanded our
analysis of patients with stage B disease to an additional 84 samples,
after failing to detect any mutation in the initial nonmicrodissected 15
specimens. Despite this precaution, we were unable to detect any
mutations in the stage B patients analyzed, regardless of enrichment
with genomic DNA extracted from tumor. However this may simply
reflect a feature of stage B prostate cancers where few AR mutations
are present; tumor enrichment may very well be important to facilitate
detection of mutations in more advanced cancers. This argument is
confirmed by the identification of AR mutations in group 2B (micro-
dissected) and not 2A (nonmicrodissected). It is likely that more
sensitive techniques, such as laser microdissection, will improve our
ability to detect AR mutations in specimens where nonmalignant
tissue has carefully been removed.
An additional variable may be the analysis of exon 1. Tilley et al.
(34) have identified the majority of their mutations in this segment of
AR. Many investigators have neglected analysis of exon 1 for differ-
ent reasons. It is difficult to obtain sufficient DNA to perform 16 PCR
amplifications. In addition, many authors have been influenced by the
molecular analysis of AR in patients with androgen resistance syn-
dromes, where the majority of the mutations were identified in exons
2–8. We were unable to study the incidence of mutations in exon 1 of
groups 1A, 2A, and 2B; however, no mutations were detected in exon
1 of group 1B. Again, this may simply reflect the low prevalence of
AR mutations in prostate cancer at this early stage.
A final methodological variable that may have overinflated the
number of mutations in other series is the use of DNA derived from
paraffin-embedded tissue. As noted above, a large number of base
changes were detected only in archival tissue, suggesting that the
process of paraffin embedment has detrimental effects on the quality
of genomic DNA. However, one could argue that the absence of SSCP
variants in exon 2 of PR in paraffin-embedded tissue should rule out
artifact as the cause of these irreproducible base changes. This issue
has been investigated in a concomitant investigation,5 where we have
performed parallel sequence analysis of DNA coming from paraffin-
embedded and frozen tissue without SSCP bandshifts. This analysis
demonstrated that irreproducible base changes are uniquely present in
DNA derived from paraffin-embedded tissue. Thus, our experience
suggests that extreme care should be placed in interpreting data
derived from genomic DNA extracted from paraffin-embedded tissue.
Nonetheless, our stringent criterion for identification of mutations
(i.e., a high percentage of a single mutation by sequencing multiple
independent PCR reactions) rules out the possibility that the differ-
ence we observed between stages B and D1 disease is a function of
differences in the tissue processing.
Conclusions
An investigation into the role played by AR mutations on the
natural history of prostate cancer was particularly needed in view of
the controversial data reported in the literature. The data presented
suggest that this molecule does not play a significant role in the initial
phases of prostate cancer, other than signaling its normal functions.
Interestingly, a relatively high number of mutations were detected in
metastatic tissue, arguing for a contribution by variant AR molecules
to the development of metastatic disease and/or androgen-independent
growth. Although a careful functional analysis of these mutations will
clarify the basic biology of their contribution to disease progression,
ongoing studies are evaluating other aspects of AR mutations in
prostate cancer, such as their prevalence in patients that have failed
hormonal treatments, and in specimens obtained from the same patient
before and after androgen-ablative treatments.
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